ADHD and menopause: the central scientific question
For an adult with attention-deficit/hyperactivity disorder (ADHD), perimenopause may coincide with changes in concentration, working memory, emotional regulation, sleep, and the ability to manage everyday responsibilities. Those experiences warrant careful clinical attention. The strongest scientific conclusion is more specific than the familiar claim that menopause automatically makes ADHD worse: reproductive aging can generate cognitive and affective symptoms that overlap with ADHD; some people with established ADHD report increased impairment during this transition; and direct evidence that menopausal hormone changes cause a predictable worsening of ADHD remains limited. Research now includes an exploratory cross-sectional study of 656 midlife women, qualitative interviews with women with ADHD, and a 2026 clinical narrative review, but longitudinal, mechanistic, and treatment trials specific to diagnosed ADHD at menopause remain scarce. Chapman et al., 2025; Kini-Seery et al., 2026; Wynchank and Kooij, 2026.
The practical question is therefore not whether every midlife difficulty should be attributed to one hormone or one diagnosis. It is how a clinician can identify preexisting ADHD, characterize a new or changing symptom pattern, investigate sleep, mood, physical health and menopause-related complaints, and choose evidence-based care for each condition. The distinctions matter because an ADHD diagnosis has a developmental history, whereas the menopausal transition has its own clinical chronology and causes of impairment. NICE NG87; Maki and Jaff, 2022.
What menopause, perimenopause, and postmenopause mean
Menopausal stages are defined by reproductive aging
Menopause is retrospectively established after 12 consecutive months without menstrual bleeding when another physiological or pathological explanation is absent. Perimenopause includes the menopausal transition and the early period around the final menstrual period. Cycles may become variable, vasomotor symptoms may emerge, and estradiol and follicle-stimulating hormone levels may fluctuate substantially. Postmenopause refers to the years after the final menstrual period. Surgical removal of both ovaries causes an abrupt endocrine transition and requires its own clinical interpretation. Harlow et al., 2012.
The STRAW+10 staging framework uses menstrual bleeding patterns as central clinical markers and provides a shared research vocabulary. A single blood hormone result does not reliably reconstruct the entire trajectory of natural perimenopause. Menstrual history, age, symptoms, medications, contraception, and clinical circumstances shape interpretation. An individual experiencing irregular bleeding should also be evaluated for other appropriate gynecological causes rather than having every change attributed to normal aging. Harlow et al., 2012.
The transition has multiple physiological pathways
The menopausal transition can involve hot flashes, night sweats, sleep interruption, altered mood, genitourinary symptoms, and perceived cognitive inefficiency. Daytime concentration may suffer indirectly when night sweats fragment sleep; irritability may rise during sustained insomnia; and worry about memory may intensify attention to ordinary mistakes. These processes can interact with ADHD-associated organizational burdens and with work or caregiving demands. That interaction is clinically plausible, while the size and direction of its effect differ by person and have not been quantified reliably in diagnosed ADHD cohorts. Metcalf et al., 2023; Maki and Jaff, 2022.
ADHD remains a neurodevelopmental diagnosis
ADHD is classified as a neurodevelopmental disorder involving developmentally inappropriate and impairing patterns of inattention and/or hyperactivity-impulsivity across important settings. The expression of symptoms and the environments that expose them can change across the lifespan. The presence of midlife difficulty organizing tasks, forgetting appointments or maintaining focus is insufficient on its own to establish ADHD. A careful assessment seeks evidence of symptoms beginning during childhood, persistence or evolution over time, functional impairment, and alternative or co-occurring explanations. NICE NG87; Young et al., 2020.
Some women have their ADHD recognized late because earlier presentations were subtle, compensated for through effort, or interpreted through other diagnoses. Increased work complexity and changes in family responsibilities may make longstanding difficulties newly visible. Menopause can also bring new cognitive symptoms to someone who never had ADHD. Both situations deserve an independent developmental history. See the published scientific discussions of adult ADHD diagnosis and recognition in women and girls.
ADHD symptoms and executive-function complaints are distinct concepts
Inattention is a symptom domain in ADHD diagnostic criteria. Hyperactivity and impulsivity are other symptom domains. Executive functions describe cognitive control operations, including working memory, inhibition, flexible shifting, planning and regulation of goal-directed activity. An adult may report executive difficulties during perimenopause without meeting ADHD criteria. Conversely, a person can meet ADHD criteria even when selected neuropsychological scores fall within normative ranges. A symptom inventory, an executive-function questionnaire and a clinical diagnosis answer different questions. NICE NG87.
The hormonal hypothesis: what biology can and cannot establish
Estradiol, neural signaling, and cognition
Estradiol acts on multiple neural systems relevant to memory, stress responses, reward processing and cognitive control. Experimental and neurobiological work supports interactions between ovarian steroids and neurotransmitter pathways, including dopamine. Such mechanisms provide a scientific reason to investigate menopausal transitions in people with ADHD. They do not yet provide an individual biomarker, a dose-adjustment formula, or proof that estradiol decline causes worsening of ADHD symptoms. Translational mechanisms, observations in healthy volunteers, and clinical outcomes in people with diagnosed ADHD occupy different levels of evidence. Metcalf et al., 2023; Wynchank and Kooij, 2026.
During perimenopause, hormonal variability may matter as much as the eventual lower postmenopausal estradiol level. However, between-person differences in reproductive stage, sleep, trauma exposure, medication, comorbidity and measurement make any single-hormone explanation inadequate. A temporal correlation between a change in cycles and a change in functioning is a useful clinical observation and a starting hypothesis for research, not a stand-alone causal test. Harlow et al., 2012; Chapman et al., 2025.
Estrogen is not an established ADHD severity biomarker
Serum estradiol, progesterone and follicle-stimulating hormone levels vary by menstrual stage and clinical circumstances. No validated threshold currently identifies menopausal worsening of ADHD or determines which ADHD medication dose will work. Clinicians may evaluate endocrine or gynecological conditions when indicated, but using serial estrogen tests alone to direct ADHD treatment extends beyond available clinical evidence. The diagnostic foundation remains symptoms, history, impairment, competing explanations and longitudinal follow-up. NICE NG87; Wynchank and Kooij, 2026.
What direct studies of ADHD and menopause have found
A 2025 study of 656 women
Chapman, Gupta, Hunter and Dommett examined 656 women aged 45 to 60, including 245 with a reported existing ADHD diagnosis. Participants completed an adult ADHD symptom measure and questionnaires covering menopause-related experiences, quality of life and hot-flash interference. In analyses corrected for multiple comparisons, the investigators found no significant main effects of ADHD diagnosis or diagnosis-by-menopausal-stage interactions on menopausal complaints. Analyses grouping women by ADHD medication status likewise did not show the predicted group or interaction effects. Across participants, ADHD symptom scores correlated with menopause complaint measures, but these associations were generally less prominent within the diagnosed ADHD group. Chapman et al., 2025.
This finding is important because it challenges a simple, universal narrative in which women with ADHD necessarily experience more severe menopausal symptoms. It does not prove that hormones have no ADHD-relevant effects. The study was cross-sectional, relied on questionnaires and clinical group characteristics, and could not establish within-person symptom trajectories before, during and after the transition. Selection effects, differing treatment histories and overlap between questionnaire items also complicate interpretation. The most defensible conclusion is that group-level evidence for a predictable ADHD-by-stage effect remains unconfirmed. Chapman et al., 2025.
A 2026 qualitative study of lived experience
Kini-Seery and colleagues interviewed 19 women with ADHD living in Ireland. Participants described changes in cognition, emotional experience, physical and sexual health, and encounters with health services. The thematic analysis also identified experiences of growing self-understanding and adaptive responses. These accounts show what it can feel like when ADHD-related vulnerabilities and perimenopausal symptoms occur in the same life period. They support patient-centered questions about everyday impairment and access to integrated care. Kini-Seery et al., 2026.
Qualitative inquiry captures meaning, context and experiences that standardized scores may miss. Its sampling and design do not estimate population prevalence, treatment effectiveness or a hormonal causal pathway. The 19 interviews and the 656-person survey therefore provide complementary forms of evidence, and their findings should be read together rather than ranked as mutually exclusive claims. Kini-Seery et al., 2026; Chapman et al., 2025.
The 2026 clinical pharmacology review
Wynchank and Kooij reviewed the pharmacological management of ADHD in women across perimenopause, menopause and postmenopause. The paper discusses attention symptoms, mood, sleep, vasomotor complaints, medication monitoring and the possibility of coordinated menopause and ADHD care. Critically, the authors acknowledged that randomized controlled trials specifically testing ADHD pharmacotherapy in perimenopausal women were unavailable and that present recommendations rely heavily on expert interpretation, general adult evidence and small observational datasets. A narrative clinical review is useful for identifying practical considerations and research gaps, but it is not itself a randomized treatment trial. Wynchank and Kooij, 2026.
Current evidence grading
Established: menopause is a reproductive-aging transition with recognized vasomotor, sleep and cognitive complaints; ADHD is a neurodevelopmental disorder requiring a developmental and functional assessment; these clinical pictures can overlap. Supported but context-dependent: some adults with ADHD experience substantial additional midlife burdens, and menopausal complaints may worsen practical functioning through sleep and affective mechanisms. Preliminary: particular hormonal fluctuations directly change ADHD symptom severity or medication response. Unproven: that all women with ADHD deteriorate at perimenopause, that hormone replacement treats ADHD, or that a universal menopause-specific stimulant dose is indicated. Maki and Jaff, 2022; Chapman et al., 2025; Wynchank and Kooij, 2026.
Cognitive symptoms during perimenopause
Memory and the experience of brain fog
Brain fog is a common descriptive expression for subjective problems with memory, mental clarity or concentration. It is not a formal ADHD diagnosis and does not define a unique neuropathological disease. Menopause research consistently documents that some midlife women perceive substantial cognitive change; evidence concerning objective performance is more nuanced. Studies indicate particular vulnerability in verbal learning and memory, with heterogeneous results for attention, speed and working memory. Maki and Jaff, 2022; Metcalf et al., 2023.
An updated systematic review and meta-analysis of perimenopausal cognitive function synthesized a wider contemporary evidence base, underscoring the importance of how reproductive stages and cognitive domains are defined. A pooled study finding is not a diagnostic criterion for an individual and cannot by itself establish a menopause-related deterioration in people already diagnosed with ADHD. Bangle et al., 2026.
Working memory, initiation, and planning
A person might describe losing the thread of a task, forgetting why they entered a room, delaying paperwork or struggling to manage several competing demands. In ADHD these difficulties may reflect longstanding executive-function burdens. Around menopause, fatigue, hot flashes, insomnia, mood symptoms or increasing responsibilities can magnify similar complaints. Their coexistence means that an assessment should establish timing, persistence, settings and functional consequences rather than assuming the cause from the symptom's wording. Metcalf et al., 2023; NICE NG87.
Why subjective and objective cognition can diverge
Questionnaires measure how cognitive difficulty is experienced within daily life. Laboratory measures assess performance on specific tasks under standardized conditions. Poor sleep, emotional symptoms, expectations, competing commitments and test environments affect the relationship between the two. A person may function adequately during a brief structured test yet struggle badly when self-managing hours of unstructured work. Equally, high concern about memory may coexist with normal task scores. Both kinds of data have clinical value when interpreted in context. Maki and Jaff, 2022; Metcalf et al., 2023.
The overlap with sleep, mood, and physical health
Hot flashes, night sweats, and disrupted sleep
Vasomotor symptoms can interrupt sleep and produce daytime fatigue, slower thinking and reduced persistence. ADHD is also associated with sleep difficulties across the lifespan, and stimulant medication timing can sometimes influence sleep. When a midlife adult reports new inattentiveness, a sleep history is central: schedule, awakening frequency, nighttime vasomotor symptoms, restless legs, apnea risk, medication effects, alcohol intake and daytime sleepiness are all relevant. The distinction between chronic ADHD-related difficulties and a superimposed sleep problem often becomes clearer with a timeline. See ADHD and Sleep: Insomnia, Circadian Rhythms, and Daytime Symptoms. NICE NG87; Metcalf et al., 2023.
Anxiety, depression, and emotional reactivity
Perimenopause is a period when some individuals experience changes in mood and affective symptoms; a history of depression, psychosocial stress and sleep disruption can be relevant. Anxiety may cause concentration problems through worry, and depression may diminish energy, initiative and memory efficiency. ADHD-associated emotional dysregulation can contribute a separate pattern of longstanding reactivity. Clinical evaluation distinguishes episodic mood change, sustained anxious rumination, pervasive low mood, and chronic executive or attentional symptoms, while also considering that these states may coexist. Metcalf et al., 2023; ADHD and Emotional Dysregulation.
Thyroid disease, anemia, medication effects, and other alternatives
Midlife cognitive complaints may coincide with thyroid dysfunction, anemia, nutritional deficiencies when clinically relevant, chronic pain, metabolic disease, medication side effects, sleep apnea or other medical conditions. Cognitive deterioration that is rapidly progressive, accompanied by new neurological abnormalities, or markedly disproportionate to everyday menopausal complaints requires timely medical assessment. A thorough history and targeted examination guide laboratory investigations; indiscriminate testing and assumptions about hormones can obscure a treatable cause. Clinical ADHD evaluation appropriately considers physical health and medication history. NICE NG87.
Recognizing ADHD in midlife without misdiagnosing menopause
Reconstructing the developmental timeline
The central question for a new ADHD diagnosis is whether the characteristic inattentive and/or hyperactive-impulsive pattern existed before midlife. A clinician may ask about childhood school reports, chronic disorganization, task completion, time management, forgetfulness, lost objects, restlessness and impairment across contexts. Historical evidence can come from the patient's own account and available collateral information; childhood documentation may be incomplete. Recognition after menopause is possible because a longstanding condition can be diagnosed late. Sudden onset of attentional symptoms exclusively during a hormonal transition calls for a broader differential assessment. NICE NG87; Young et al., 2020.
Develop a symptom-by-time map
A useful clinical timeline separates symptoms before the menopausal transition, new experiences emerging with menstrual changes, fluctuating symptoms related to poor nights of sleep, major life stressors, medication changes and sustained changes in functional demands. Temporal diaries can help identify associations between sleep disruption, hot flashes, attention, mood and daily functioning. They are observations, not experimental demonstrations of hormone causality. Symptoms that improve when insomnia or depression is successfully treated may reveal the contribution of those conditions, even if ADHD remains present. Maki and Jaff, 2022; NICE NG87.
Screening instruments and their limits
The Adult ADHD Self-Report Scale can identify symptom patterns requiring further inquiry, but symptom endorsements may also reflect sleep loss, anxiety, depression and menopausal cognitive complaints. Rating scales may help track change over time, and menopause-specific instruments can assess vasomotor and health-related burden. Neither kind of questionnaire replaces a comprehensive clinical interview. A high screening score does not settle whether the symptom origin is neurodevelopmental, menopause-related or mixed. Chapman et al., 2025; NICE NG87.
Neuropsychological tests and clinical judgment
Attention, memory and executive-function tests may be appropriate when clinicians need to clarify a specific cognitive question, assess unusual deterioration or consider neurologic disease. Results depend on the test, reference norms, education, language and health status. ADHD is diagnosed clinically rather than by a single test score, brain scan, hormone panel or online questionnaire. Midlife cognitive assessment should ask what tests can contribute to the particular decision being made and how performance relates to real-world functioning. NICE NG87; Maki and Jaff, 2022.
Care coordination and treatment principles
Treat each established clinical target on its own evidence base
A useful treatment plan specifies the target: ADHD symptoms and impairment, vasomotor symptoms, insomnia, depressed mood, anxiety, functional organization or another medical condition. One intervention may improve more than one outcome indirectly, but its evidence must be tied to the outcome actually studied. Adult ADHD guidelines support evidence-based medication and targeted psychological or environmental support when appropriate; menopause position statements address hormonal and nonhormonal management of menopause symptoms. Treatment selection depends on individual history, contraindications, goals and ongoing review. NICE NG87; The Menopause Society, 2022.
ADHD medication during perimenopause
For adults with a verified ADHD diagnosis and significant impairment, methylphenidate or lisdexamfetamine are guideline-supported first-line options in NICE guidance. Atomoxetine is an established nonstimulant option when first-line agents are unsuitable or insufficiently effective. Choice and titration require attention to coexisting illness, blood pressure, heart rate, sleep, appetite, weight, interactions, and the response of everyday functioning. In perimenopause these considerations may be particularly relevant because insomnia, hot flashes, anxiety and cardiovascular risk factors can also change. Evidence does not justify an automatic stimulant increase whenever menstrual cycles become irregular. NICE NG87; Wynchank and Kooij, 2026.
A clinician reviewing an existing ADHD prescription should examine whether the reported deterioration is persistent or sleep-dependent, whether symptoms vary with medication timing, whether adverse effects have emerged, and whether the person's actual functional targets remain responsive. NICE recommends heart rate and blood pressure checks before and after dose changes and at least every six months, alongside ongoing effectiveness and adverse-effect monitoring. Individual dose changes require the treating prescriber's evaluation, especially when other medications or cardiovascular conditions are present. NICE NG87.
What the lisdexamfetamine menopause experiments actually studied
A small double-blind placebo-controlled crossover study enrolled 32 healthy perimenopausal or early postmenopausal women who reported new-onset executive difficulties. Lifetime ADHD was an exclusion criterion. Four weeks of lisdexamfetamine improved questionnaire-rated executive complaints and one delayed verbal-recall outcome compared with placebo, while other objective cognitive measures did not significantly improve. A separate small neuroimaging study in 14 women without ADHD investigated neural activation and neurochemistry during stimulant exposure. These are studies of menopause-associated executive complaints in people without diagnosed ADHD, not evidence that stimulants treat menopause, establish an ADHD diagnosis or should be prescribed routinely for menopausal brain fog. Epperson et al., 2015; Lisdexamfetamine neuroimaging study, 2016.
These experimental results illustrate both pharmacologic plausibility and the importance of correct population labels. Short trials with small samples cannot establish long-term safety or clinical benefit for the broad menopausal population, and they do not answer whether ADHD medication needs different dosing during perimenopause. The 2026 pharmacology review specifically identifies the absence of randomized treatment trials in women with diagnosed ADHD during this transition. Wynchank and Kooij, 2026.
Menopausal hormone therapy: established indications and boundaries
Menopausal hormone therapy is an effective treatment for bothersome vasomotor symptoms and can be appropriate for other menopause-related indications after individualized benefit-risk assessment. Selection of formulation, route, dose and duration depends on age, time since menopause, uterine status, personal history and contraindications. An intact uterus ordinarily requires endometrial protection when systemic estrogen is prescribed. Breast cancer history, thromboembolic events, unexplained vaginal bleeding and cardiovascular factors may materially affect eligibility. These are matters for individualized menopause care rather than a one-size-fits-all strategy. The Menopause Society, 2022.
Hormone therapy is not an established ADHD treatment. Reviews of menopausal hormone therapy and cognition have found heterogeneity by formulation, age, surgical versus natural menopause and outcome, with no overall improvement across cognitive domains in a 2024 meta-analysis of randomized trials. International recommendations do not endorse menopausal hormone therapy as a routine strategy to treat cognitive decline or prevent dementia. A person with ADHD who receives menopausal hormone therapy for an accepted clinical indication may experience better sleep or well-being when vasomotor symptoms improve, but that observation does not demonstrate direct treatment of core ADHD symptoms. Andy et al., 2024; International Menopause Society, 2025.
Nonhormonal menopause care and behavioral treatment
For troublesome hot flashes and night sweats when hormone therapy is unsuitable or not preferred, evidence-based nonhormonal options include selected prescription therapies and structured interventions. The Menopause Society's 2023 statement evaluates cognitive behavioral therapy and clinical hypnosis, some antidepressants, gabapentin and other medical options for vasomotor symptoms according to the specific evidence and safety profile. Those recommendations do not imply that all these treatments improve ADHD. Likewise, exercise and relaxation may support general health and coping without being established substitutes for indicated ADHD or menopause care. The Menopause Society, 2023.
Psychological treatment for adults with ADHD may address planning, emotion regulation, task management and maladaptive coping. Environmental adjustments, calendars, task cues, deliberate routines and written instructions can reduce the demands placed on prospective memory. Such strategies are individualized functional supports rather than hormone treatments or validated diagnostic tests. Their use alongside assessment of sleep and menopause-specific symptoms is clinically coherent. See ADHD Treatment Without Medication: Behavioral and Environmental Support. NICE NG87.
Everyday functioning, identity, and access to care
Work, decision-making, and cumulative load
Midlife often brings simultaneous responsibilities involving employment, family care, finances, health appointments and changing social roles. If longstanding ADHD requires substantial effort to maintain organization, additional insomnia or cognitive complaints can exhaust an already heavily used set of compensatory strategies. A person may notice more missed meetings, unfinished administrative work or difficulty recovering after interruptions. Clinical decisions should consider demands, available support and impairment, not just symptom ratings detached from the person's environment. Kini-Seery et al., 2026; Young et al., 2020.
Written agendas, reduced task switching, external reminders, breaks, predictable scheduling and reasonable workplace adjustments can lower functional burden. Where possible, the person and their clinician can define a few observable goals, such as reducing missed appointments or improving work-task completion, and revisit them after treatment changes. Because menopause-related symptoms may fluctuate, reviewing a pattern over weeks provides more useful information than reacting to one difficult day. These are pragmatic supports tailored to individual goals rather than interventions proven to correct an endocrine mechanism.
Relationships and emotional context
Sleep disruption, sexual symptoms, pain and mood changes may affect intimate relationships and family communication. ADHD-associated forgetfulness, impulsive responding or difficulties organizing shared obligations can create additional friction. It is useful to identify which problems are longstanding, which are new and which improve when communication or health symptoms are addressed. Respectful clinical care recognizes that the person may be managing several legitimate burdens simultaneously. Qualitative research underscores how women with ADHD value coordinated discussion of psychological, sexual, cognitive and physical experiences. Kini-Seery et al., 2026.
The risk of diagnostic overshadowing
Diagnostic overshadowing occurs when a familiar condition becomes the default explanation for all new symptoms. If an adult has an established ADHD diagnosis, new severe insomnia, persistent low mood or a medical disorder might be overlooked. If an adult is in perimenopause, a lifelong pattern of ADHD-related impairment might be dismissed as ordinary menopause. Both errors can delay appropriate care. Good assessment maintains an accurate developmental picture while making room for a second or third condition. NICE NG87; Young et al., 2020.
Diversity of menopausal experiences
Research has often centered cisgender women undergoing natural menopause. Gender-diverse adults, people with early or surgical menopause, and people using gender-affirming hormones may have substantially different endocrine histories and access barriers. ADHD studies in these populations are especially limited. Clinical care can assess reproductive history and current symptoms respectfully, and the scientific literature should avoid generalizing from one recruitment group to all individuals who experience ovarian aging or related hormonal change.
Unresolved methodological questions
Cross-sectional associations and causality
When researchers measure ADHD symptoms and menopausal complaints on the same occasion, correlated scores may arise because questionnaires measure overlapping concentration, sleep and affective experiences. They may also reflect shared upstream factors such as health burden or stress. Cross-sectional designs cannot establish whether hormones preceded the symptom change, whether mood and sleep mediated the association, or whether increased ADHD-related impairment changed the perception of menopause symptoms. Prospective designs with repeated measures are needed. Chapman et al., 2025.
Accurate menopause staging and ADHD case definitions
Different studies may define menopausal stage through menstrual history, age, self-identification or hormone results, producing groups that are not directly comparable. Similarly, ADHD status can mean a documented clinical diagnosis, past self-report, current screening score or medication prescription. These definitions represent different populations. To test an ADHD-specific menopausal mechanism, future cohorts need explicit ADHD diagnostic ascertainment, standardized reproductive staging, pretransition baselines, co-occurrence assessments and transparent medication records. Harlow et al., 2012; Chapman et al., 2025.
Outcomes that matter to patients
A robust study should not rely solely on an improvement in a questionnaire total. It should assess day-to-day functioning, occupational participation, self-defined priorities, sleep, mood, quality of life and adverse effects. Objective attention measures can add insight but should not be mistaken for complete summaries of a person's functioning. An intervention that decreases hot flashes may improve sleep and consequently concentration even without directly changing ADHD. Distinguishing these causal pathways is essential to claiming that a treatment specifically modifies ADHD during menopause. Metcalf et al., 2023; Wynchank and Kooij, 2026.
Clinical trials and the limits of extrapolation
Treatment effects in younger adults with ADHD cannot be assumed identical in midlife adults with changing sleep, comorbidity, cardiovascular status and other medication use. Nor can stimulant effects in women without ADHD who have newly developed executive complaints be carried over to women with diagnosed ADHD. The priority research questions include whether reproductive stage modifies established ADHD treatments, whether menopause interventions indirectly reduce functional ADHD burden, and how combined treatments compare with coordinated single-condition care. Such trials require adequate power, safety monitoring and long-term follow-up. Epperson et al., 2015; Wynchank and Kooij, 2026.
Clinical questions frequently asked
Can perimenopause make established ADHD feel worse?
Yes, an individual may experience increased impairment when sleep loss, vasomotor symptoms, mood changes or cognitive complaints add to existing ADHD difficulties. Reports from women with ADHD document such experiences. Current research has not established a uniform biological worsening of ADHD across menopause stages, and the 2025 cross-sectional comparison did not detect the predicted group-level increase in menopausal complaints among women with ADHD. Care should examine the person's actual symptom timeline and functioning. Kini-Seery et al., 2026; Chapman et al., 2025.
Can ADHD begin for the first time at menopause?
A first recognition of ADHD can occur in midlife, while the disorder's diagnostic history still traces back to childhood. New attention complaints appearing solely during perimenopause require investigation for sleep disruption, mood conditions, medical illness, medication effects and menopause-associated cognitive changes. An adult assessment reconstructs developmental symptoms and impairment rather than relying on current cognitive complaints alone. NICE NG87.
Do estrogen tests prove that ADHD symptoms are hormonal?
No validated blood hormone threshold establishes that an ADHD symptom change is caused by perimenopause. Menopausal staging depends on reproductive and clinical history, and hormone measurements vary over time. Tests may be appropriate for particular medical questions but cannot substitute for an ADHD assessment or determine ADHD medication dosing. Harlow et al., 2012; NICE NG87.
Does menopausal hormone therapy treat ADHD or brain fog?
Hormone therapy has recognized indications for menopause-related symptoms, particularly vasomotor symptoms. It is not established as a treatment for core ADHD symptoms or as routine therapy for cognitive decline. For a patient with both conditions, treating an indicated menopause symptom may improve sleep and perceived functioning, but benefit should be assessed for the actual target. Andy et al., 2024; International Menopause Society, 2025.
Should ADHD stimulant doses be increased around menopause?
There is no validated menopause-specific stimulant adjustment schedule. Any change should be based on documented symptoms, functional response, side effects and safety considerations, with a qualified prescriber. Clinicians should examine sleep disruption and physical or emotional conditions that might explain the changed experience before attributing it to reduced medication efficacy. NICE NG87; Wynchank and Kooij, 2026.
When is prompt medical evaluation important?
Rapidly progressive confusion, new focal neurological symptoms, severe depression, marked impairment or safety concerns warrant timely evaluation under appropriate medical pathways. Suicidal thoughts require immediate assessment and support, regardless of whether ADHD or menopause is present. New, unexplained bleeding or major physical symptoms also deserve appropriate medical review. The research on hormonal transitions does not justify withholding care for potentially urgent conditions.
Scientific conclusion
ADHD and menopause converge at a clinically meaningful point in adult development: both can shape attention, self-regulation, emotional experience and daily function, and their effects may accumulate through sleep and life circumstances. The direct science is younger and less definitive than popular narratives imply. The 2025 survey does not support an automatic group-level increase in menopausal complaints among women with ADHD, while 2026 qualitative work documents diverse lived experiences of combined burden. Existing menopause and ADHD guidelines support careful differential diagnosis, treatment of verified conditions and individualized monitoring. The most valuable next scientific advances will come from longitudinal studies and randomized trials that distinguish reproductive physiology, core ADHD symptoms and meaningful everyday outcomes. Chapman et al., 2025; Kini-Seery et al., 2026; Wynchank and Kooij, 2026.
Related Articles
Cluster ADHD and Executive Function — The published scientific chapter covering ADHD classification, mechanisms, lifespan development and care.
ADHD in Women and Girls: Recognition, Masking, and Clinical Care — Recognition bias, lifespan presentation and clinical care.
Adult ADHD Diagnosis: Clinical Criteria, Assessment, and Differential Diagnosis — Developmental history, criteria and competing explanations for adult symptoms.
ADHD and Sleep: Insomnia, Circadian Rhythms, and Daytime Symptoms — Sleep-related cognitive difficulties and their evaluation.
ADHD and Emotional Dysregulation: Reactivity, Irritability, and Evidence — Differentiating emotional symptoms, evidence and co-occurring disorders.
ADHD in Older Adults: Diagnosis, Aging, and Differential Assessment — Later-life evaluation and differentiation of cognitive complaints.
References
Andy, C., Nerattini, M., Jett, S., et al. (2024). Systematic review and meta-analysis of the effects of menopause hormone therapy on cognition. Frontiers in Endocrinology, 15, 1350318. https://doi.org/10.3389/fendo.2024.1350318.
Bangle, A., Williams, D., Walters, J., and Nguyen, L. (2026). Cognitive functioning in perimenopause: An updated systematic review and meta-analysis. Psychology and Aging, 41(3), 303–318. https://doi.org/10.1037/pag0000946.
Chapman, L., Gupta, K., Hunter, M. S., and Dommett, E. J. (2025). Examining the link between ADHD symptoms and menopausal experiences. Journal of Attention Disorders, 29(14), 1263–1277. https://doi.org/10.1177/10870547251355006.
Epperson, C. N., et al. (2015). New onset executive function difficulties at menopause: A possible role for lisdexamfetamine. https://pubmed.ncbi.nlm.nih.gov/26063677/.
Harlow, S. D., Gass, M., Hall, J. E., et al. (2012). Executive summary of the Stages of Reproductive Aging Workshop +10: Addressing the unfinished agenda of staging reproductive aging. Fertility and Sterility, 97(4), 843–851. https://doi.org/10.1016/j.fertnstert.2012.01.128.
International Menopause Society. (2025). IMS recommendations and key messages on women's midlife health and menopause. https://doi.org/10.1080/13697137.2025.2585487.
Kini-Seery, C., Trevaskis, S., Kilbride, K., Wrigley, M., and Bramham, J. (2026). Hormones rule me: A qualitative exploration of the impact of perimenopause on women with ADHD. Women's Health, 22. https://doi.org/10.1177/17455057261450178.
Maki, P. M., and Jaff, N. G. (2022). Brain fog in menopause: A health-care professional's guide for decision-making and counseling on cognition. Climacteric. https://doi.org/10.1080/13697137.2022.2122792.
Metcalf, C. A., Duffy, K. A., Page, C. E., and Novick, A. M. (2023). Cognitive problems in perimenopause: A review of recent evidence. Current Psychiatry Reports, 25, 501–511. https://doi.org/10.1007/s11920-023-01447-3.
National Institute for Health and Care Excellence. (2018; current online guidance). Attention deficit hyperactivity disorder: Diagnosis and management (NG87). https://www.nice.org.uk/guidance/ng87/chapter/recommendations.
Shanmugan, S., Loughead, J., Nanga, R. P. R., et al. (2017). Lisdexamfetamine effects on executive activation and neurochemistry in menopausal women with executive function difficulties. Neuropsychopharmacology, 42(2), 437–445. https://doi.org/10.1038/npp.2016.162.
The Menopause Society. (2022). The 2022 hormone therapy position statement. https://www.menopause.org.au/health-professionals/position-statements/nams-2022-hormone-therapy-position-statement/.
The Menopause Society. (2023). The 2023 nonhormone therapy position statement. Menopause, 30(6), 573–590. https://doi.org/10.1097/GME.0000000000002200.
Wynchank, D., and Kooij, S. (2026). Pharmacological management of ADHD in women across perimenopause, menopause and post-menopause. Drugs and Aging, 43(5), 385–395. https://doi.org/10.1007/s40266-026-01291-z.
Young, S., Adamo, N., Ásgeirsdóttir, B. B., et al. (2020). Females with ADHD: An expert consensus statement taking a lifespan approach providing guidance for the identification and treatment of attention-deficit/hyperactivity disorder in girls and women. BMC Psychiatry, 20, 404. https://doi.org/10.1186/s12888-020-02707-9.